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I. Introduction
In recent years, knowledge-based treatment planning (KBP) has garnered significant interest from both the academic and clinical communities. KBP exploits information from historical treatment plans to predict metrics for new treatment plans. These predicted metrics can be used as a reference for creating new treatment plans, as a quality control 55 tool during traditional treatment planning, or as part of an automated treatment planning framework.
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Most research on KBP leverages machine learning methods in combination with patient anatomical features to predict plan quality metrics or treatment plan parameters. The quantity and quality of treatment plans used to train these models can directly 60 influence the accuracy of the predicted metrics. In general, a larger pool of historical plans increases the observed variations in organ geometries, allowing the model to exploit this information to make more accurate predictions.
Based on the predicted endpoint, KBP methods generally fall into one of three categories.
The first approach seeks to predict specific points on an organ-at-risk (OAR) dose-volume 65 histogram (DVH). [7] [8] [9] [10] [11] Generally, the predicted DVH points correspond to clinical quality control or acceptability criteria, which are subsequently used as dosimetric goals during the planning process. The second approach attempts to predict the complete DVH curve for each OAR. 12-14 The predicted DVH curve may then be used as a reference plan in standard planning approaches or as a target plan during treatment planning optimization. The final 70 approach predicts optimization objective function weights, which correspond to the relative importance of each OAR. 15, 16 These weights are then used to generate a treatment plan that can be used as an advanced starting point during treatment planning.
KBP has garnered substantial interest from commercial treatment planning software companies. KBP solutions may be developed in-house, as discussed above, or will usually help create a more robust model." 17 In particular, we aim to scientifically determine the minimum number of plans required to create an accurate KBP model. This fundamental topic has not yet been explored in the academic literature and, given the trend toward clinical implementation of KBP, requires immediate attention.
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In this study, we develop an experimental methodology to determine the minimum number of treatment plans required to create an accurate KBP model. We select four models from the three KBP approaches described above and apply our methodology to investigate how the size of the training set (i.e., "sample size") influences the quality of predicted endpoints.
The predicted endpoints
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we analyze are the specific quantifies that are output from the various prediction methodologies, which can be used in a subsequent treatment planning step.
We use a large dataset of 315 prostate cancer patients from the Princess Margaret Cancer
Center to complete our experiments. We use statistical testing to estimate the minimum sample size needed to achieve consistent accuracy metrics for each KBP model. We believe 95 that because prostate cancer has relatively homogeneous anatomy, our results may provide a lower bound on the required sample size for more complicated tumor sites.
II. Methods and Materials

A. Data
This study used a previously obtained data set 16 , which contains 315 prostate IMRT 
B. Models
We selected models from the three KBP categories outlined in the introduction. We investigate a single model for both DVH point and DVH curve prediction and we consider 110 two models for objective function weight prediction. We give brief overviews of each model and refer the interested reader to the original papers for more details.
DVH point prediction
We tested the methodology proposed by for predicting bladder and rectum achievable dose metrics. 7 The goal of this methodology is to use a database of 115 previous patients with similar anatomy to predict a new patient's achievable dose.
We generated OVH curves 19 for the bladder and rectum using PTV expansions of 0 mm to 25 mm in 1 mm increments. OVH curve metrics are used in the database lookup to exclude dissimilar patients.
Let D v,i denote the dose to a specific fractional volume, v, of patient i (i.e., a point on the DVH curve). Let V 95,i denote the percentage of the PTV receiving 95% of the prescribed dose for patient i, and let r v,i denote the PTV expansion distance resulting in an overlap percentage volume of v for patient i (i.e., a point on the OVH curve). The predicted dose metric for the bladder (or rectum) of a new patient j was defined as
In this study, we set v = 30% and v = 50% for both the bladder and rectum. 
For each testing set patient, we used the loading matrices to project the 50-dimensional DTH prediction error, defined as the absolute difference between the predicted and clinical dosage, was also computed. To accomplish this, we extracted D 50 and D 30 (i.e., dose to 50% and 30% volume) from both the bladder and rectum curves.
Objective function weight prediction
We applied two weight prediction models from Boutilier et al. (2015) . 16 We chose the 155 logistic regression model as a benchmark because it performed best for prostate cancer, and we chose the K-nearest neighbor model because of its simplicity and its potential for application to more complicated tumor sites. A previously developed inverse optimization method (IOM) was applied to determine five optimal objective function weights for each patient, objective function weights are normalized so that they sum to one.
Using OVH curves, we computed the ratio of rectum overlap volume to bladder overlap volume for each PTV expansion value x ∈ {0, 1, ..., 25mm}, which we denote as OV x . Next, we computed the slope of the bladder and rectum OVH curves between each pair of consecutive expansion points in {0, 1, ..., 25mm}. We 170 denote these slopes by OV SB x,x+1 and OV SR x,x+1 for the bladder and rectum, respectively. We used these OVH related metrics as independent variables for weight prediction.
The logistic regression model used two patient features, OV 4 and OV SR 0,1 , as previously determined. 16 The functional form of the logistic regression equation was defined as
where α b denotes the bladder weight. The rectum weight was computed post hoc as α r = 1 − α b . The bladder and rectum weights were multiplied by 0.944 to accommodate nonzero 175 weights for the left femur, right femur, and PTV ring. The value of 0.944 was determined by setting the lf , rf , pr weights to their population averages as determined by the IOM.
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For the KNN model, we first used a 3-means clustering algorithm to partition the objective function weights into three distinct groups, corresponding to patients that are bladderweighted (b), rectum-weighted (r), and roughly equally weighted or balanced (a). Each patient was assigned a label corresponding to the cluster to which that patient belonged.
Using the patient labels, we trained a distance-weighted KNN model, which uses a set of patient features to determine the probability that a given patient belongs to each cluster. In particular, the KNN model used a triangular kernel function and two patient features, OV 4 and OV SB 13,14 with K = 14. 16 When the training set size is equal to 10, all neighbors are considered (i.e., K = 10). Let p i denote the probability a patient belongs to cluster i and let c i denote the centroid weight vector of cluster i. For each patient, the KNN predicted weight vector, α KN N , was defined as
Objective function weight error, defined as the absolute difference between the IOM weights and the model predicted weights, was computed for each patient.
C. Experimental Setup
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We first outline our methodology at a high level, which can be used to determine the minimum required sample size for any KBP model. First, randomly select roughly 1/3 of the patients to serve as a validation set for all experiments.
Next, consider a set of n different training set sizes starting from a sample size of 10 patients. For each value of n, randomly select 100 different training sets 185 with replacement from the remaining 2/3 patients (i.e., bootstrap). Use each of the 100 training sets to train each KBP model for each value of n. Finally, for each KBP approach, use each of the models (i.e., 100 for each n) to predict KBP endpoints for all validation set patients.
Now we specialize this general methodology and outline the specifics of our 190 experimental setup. We first set aside 100 randomly selected patients (i.e., 32%)
to serve as a validation set for all experiments. We considered eight different training set sizes corresponding to n = 10, 20, 30, 50, 75, 100, 150, and 200 patients.
For each value of n, we randomly selected 100 different training sets with replacement from the remaining 215 patients (i.e., bootstrap). Each of the 100 195 training sets was used to train each of the four KBTP models for each value of n. Finally, for each KBTP approach, we used each of the 800 models (i.e., 100
for each n) to predict the KBTP endpoints for the 100 testing set patients.
To evaluate the performance of the models, we compared what we refer to as traditional model error. For each approach, model error is defined as the variation between the predicted 200 model value and the true value for each of the 100 patients in the validation set. For each of the 100 bootstrapped training sets, we computed the median error across all 100 patients in the validation set. For illustration, we plot the distribution of error (across the bootstraps)
as a function of sample size using a series of box-and-whisker plots. To further investigate the increasing model error, we first define under-prediction as 225 predicting a dosimetric value better than the clinical (i.e., type I error) and over-prediction as predicting a dosimetric value worse than the clinical (i.e., type II error). To examine this phenomenon, we counted the number of patients that were over-predicted in each bootstrap sample. Figure 2 shows the distribution of the number of patients over-predicted for each predicted DVH point.
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For each of the four DVH point metrics, the number of patients over-predicted at each sample size from 10 to 150 was significantly different from the number of patients overpredicted at a sample size of 200. These results suggest that the number of over-predicted patients is still decreasing and a sample size of 200 or more is required to obtain consistent model predictions. 
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suggest that a sample size of at least 75 is required to obtain accurate and consistent bladder DVH predictions. For the rectum (i.e., Figure 3(b) ), only the median error at a sample size of 10 is significantly different when compared to 200. These results suggest that a sample size of at least 20 is required to obtain accurate and consistent rectum DVH predictions.
Overall, for DVH curve prediction, a sample size greater than 75 should be used to train 245 KBP models. Figures 1 and 4) .
To further illustrate the improvement in model accuracy as sample size increases, we plot DVH curves corresponding to four sample sizes for three patients. We chose one patient with poor prediction accuracy, one with average 
IV. Discussion
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With the increasing clinical interest in KBP, it is critical to understand both the advantages and limitations of KBP models for clinical implementation. In particular, institutions interested in adopting such an approach should ensure they have access to a sufficiently large training database to produce predictions with the required accuracy. Failure to adequately train KBP models may result in poor and inconsistent performance, which may negatively 285 impact future treatment plan quality and limit KBP uptake. The quality and quantity of training set samples can both impact model accuracy. In this paper, we did not consider how the quality of the training set plans impact model predictions. Instead, we used previously delivered plans of high clinical quality, and we aimed to estimate the quantity needed to achieve consistently accurate model predictions.
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The minimum required training set size was found to be different for each of the KBP set size experiments should be carried out before clinical implementation of a specific KBP model.
We observed that logistic regression requires fewer patients compared to the other methods we investigated. We hypothesize that this is because the model is correctly chosen and is able to exploit information regarding the underlying 300 distribution or shape of the data (i.e., S-shaped). In contrast, the DVH point prediction method and KNN weight prediction are non-parametric approaches.
These models are not able to exploit information regarding the underlying distribution of the data. In practice, these results suggest that logistic regression and other parametric, if well suited to the data, may require smaller training 305 set sample sizes.
The required training set size needed to predict rectum metrics appears to be smaller than the required training set size for bladder metrics. For example, rectum DVH curve prediction required at least 20 samples, while bladder DVH curve prediction required at least 75 samples. Rectum sparing is generally more difficult and therefore receives more respectively. For a given patient, over-prediction occurs when a KBP model predicts a dosimetric value that is worse than what is actually achievable. This is problematic because it may cause the planner to stop before the best possible plan is achieved. In contrast, 
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This study has some limitations. In particular, repeatedly sampling 200 patients with replacement from a total of 215 adds conservatism to our hypothesis testing. Due to the large overlap between samples of size 200, the KBP model predictions will be similar, resulting in artificially low variance. Low variance increases the power of our statistical test, leading to a higher chance of statistical significance. Since our null hypothesis is defined as equal error 330 between two different sample sizes, a higher chance of statistical significance means that the minimum required sample size may actually be overestimated.
Although we only tested our models on prostate cancer patients, we believe our results provide a lower bound on the required number of samples for other tumor sites. Compared to other tumor sites such as head-and-neck, prostate cancer patients are considered relatively 335 homogeneous, with minimal variation between the anatomy and resulting treatment plans for different patients. Moreover, due to being part of a clinical trial, our historical treatment plans are quite uniform and have the same beam angles, prescribed dose, and treatment protocols. As a result, one can expect that a small sample size is able to accurately represent the full spectrum of patients. In contrast, more complicated tumor sites may require a larger 340 pool of patients to represent the complete patient spectrum.
Automated treatment planning is a closely related topic that leverages the results of KBP approaches to automate the treatment planning process. Predicted metrics from each of the approaches tested in this paper can be used as input parameters for an automated treatment planning framework. DVH points 345 (i.e., dosimetric goals) and objective function weights can be used together or separately as optimization parameters from which an initial treatment plan is generated. DVH curves can also be used to provide input parameters, but are most often used in an alternative optimization approach that seeks to generate a treatment plan with similar DVH curves (e.g., as measured by squared error). 
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